Game-Changer for Canine Cancer: ELIAS Announces Key Hire Ahead of Revolutionary Treatment Launch
ELIAS Animal Health, a pioneering company in companion animal cancer therapeutics, has officially announced Brian Segebrecht as the new Chief Revenue Officer. This strategic appointment comes as the company prepares for the anticipated regulatory approval and subsequent commercial launch of its innovative product, ELIAS Cancer Immunotherapy (ECI®), scheduled for the fourth quarter of 2024.
Brian Segebrecht brings a wealth of experience to ELIAS, having recently led Sentrx Animal Care to a successful exit as CEO in 2023. At ELIAS, Segebrecht will spearhead the commercialization of their first-in-class adoptive cell therapy and will play a crucial role in developing business partnerships to enhance the company’s expanding product pipeline.
Tammie Wahaus, CEO of ELIAS Animal Health, expressed confidence in Segebrecht’s capabilities, stating, "Brian's proven expertise in transforming commercial strategy and building value for shareholders is exactly what we need as we approach the regulatory approval of ECI® later this year. His leadership will be vital as we not only launch our lead product but also continue to grow our portfolio of innovative cancer treatments for pets."
Segebrecht himself is enthusiastic about his new role, particularly about the potential impact of ECI®. "I am both honored and excited to join this amazing team. ECI® represents a disruptive innovation in the treatment of osteosarcoma in dogs, addressing a significant gap in current treatment modalities. I am also excited about the future innovations in ELIAS’s pipeline following ECI®."
ECI® is set to become the only approved adoptive cell therapy for treating canine osteosarcoma, following promising results from pivotal studies that led to a USDA determination of its efficacy. This marks a significant milestone not only for ELIAS Animal Health but for veterinary medicine, providing a new, effective treatment option for a devastating form of cancer that affects dogs.
In addition to preparing for the commercial launch of ECI®, ELIAS is actively seeking to raise $10 million in Series A funding. This capital will support manufacturing expansion and the commercialization efforts of ECI®, as well as fund ongoing projects in the company’s pipeline, including a novel oncolytic immunotherapy and pilot studies aimed at enhancing the application and efficacy of ECI®.
As ELIAS moves toward the commercial launch of ECI®, the therapy remains available as an experimental biologic for veterinary use under current regulations, with the company close to securing a first-in-class Autologous Prescription Product license.
For those interested in investing or learning more about the revolutionary impacts of ECI® and other upcoming therapies from ELIAS, please reach out to ir@eliasah.com.
